MOG and myeloid sarcoma: The probable prevalence of MOG seropositivity and positive MRZR in the general population can be calculated according to the estimated population-based prevalence of the respective disease (2/100.000 for MOGAD, 190/100.000 for MS) (6–8) and the disease-specific sensitivity of the respective positive diagnostic test.